RxDoctor Payments Data

Anthony Bianchi

Psychiatry · Hoover, ALNPI 1699201079

Payments from drug & device makers

$2,578in general payments, 2019–2025

Across 92 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$423
  • Johnson & Johnson$384
  • Vanda Pharmaceuticals Inc.$345
  • Teva Pharmaceuticals USA, Inc.$248
  • Neurocrine Biosciences, Inc.$206
  • Axsome Therapeutics, Inc.$195
  • plus $779 from 9 others

What the payments were for

  • Food & beverage$2,43995%
  • Education$1395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,578 in reported general payments places this provider in the 70th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$173,544
Medicare patients
306
Services billed
2,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate32$266,223
SpravatoEsketamine Hcl141$200,644
CaplytaLumateperone Tosylate41$70,112
RexultiBrexpiprazole16$33,019
FanaptIloperidone13$31,453
EliquisApixaban30$15,634
Aripiprazole163$14,546
AuvelityDextromethorphan Hbr/Bupropion12$12,847
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$6,226
Lurasidone Hcl29$5,621
Duloxetine Hcl192$5,473
Trazodone Hcl383$4,943
Memantine Hcl90$4,622
Olanzapine244$3,886
Ziprasidone Hcl56$3,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$206$266,22332 claims
Johnson & JohnsonSpravato$384$200,644141 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$423$70,11241 claims
Otsuka America Pharmaceutical, Inc.Rexulti$122$33,01916 claims
Vanda Pharmaceuticals Inc.Fanapt$345$31,45313 claims
Axsome Therapeutics, Inc.Auvelity$195$12,84712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →